| Business Summary | | CollaGenex
Pharmaceuticals,
Inc.
is
a
specialty
pharmaceutical
company
focused
on
providing
medical
therapies
to
the
dental
market.
The
Company's
first
product,
Periostat,
is
an
orally
administered,
prescription
pharmaceutical
product
and
is
the
first
and
only
pharmaceutical
to
treat
adult
periodontitis
by
inhibiting
the
enzymes
that
destroy
periodontal
support
tissues.
In
December
2000
and
February
2001,
the
United
Kingdom
Medicines
Control
Agency
and
the
United
States
Food
and
Drug
Administration,
respectively,
granted
marketing
approval
for
a
new
tablet
formulation
of
Periostat
which
is
smaller,
easier
to
swallow
and
offers
manufacturing
cost
advantages.
Currently,
the
Company
is
also
marketing
Vioxx,
a
prescription
non-steroidal
anti-inflammatory
drug
developed
by
Merck
&
Co.,
Inc.
that
the
Company
promotes
for
the
treatment
of
acute
dental
pain,
and
Denavir,
a
prescription
drug
owned
by
Novartis
Pharmaceuticals
Corporation
for
the
treatment
of
cold
sores. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CollaGenex
Pharmaceuticals
is
pharmaceutical
company
focused
on
providing
innovative
medical
therapies
for
the
treatment
of
periodontitis
and
other
pathologies
characterized
by
the
progessive
degradation
of
the
body's
connective
tissues.
For
the
six
months
ended
6/30/01,
revenues
rose
20%
to
$15.7
million.
Net
loss
before
acct.
change
applicable
to
Common
rose
26%
to
$6.2
million.
Results
reflect
higher
sales
of
Periostat,
offset
by
increased
advertising
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Brian Gallagher, Ph.D., 53 Chairman,
Pres, CEO | $438K | -- | Nancy Broadbent, 45 CFO,
Treasurer, Sec. | 254K | $19K | Robert Ashley, 43 Sr.
VP | 279K | 134K | Douglas Gehrig, 56 VP
of Sales | 244K | -- | David Pfeiffer, 38 VP
of Marketing | 304K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|